These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 20402540)

  • 1. Economic burden of multiple sclerosis: a systematic review of the literature.
    Naci H; Fleurence R; Birt J; Duhig A
    Pharmacoeconomics; 2010; 28(5):363-79. PubMed ID: 20402540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.
    Naci H; Fleurence R; Birt J; Duhig A
    J Med Econ; 2010 Mar; 13(1):78-89. PubMed ID: 20047364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of multiple sclerosis in the United States: A systematic literature review.
    Schauf M; Chinthapatla H; Dimri S; Li E; Hartung DM
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1354-1368. PubMed ID: 37976077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How much is the cost of multiple sclerosis--systematic literature review.
    Kolasa K
    Przegl Epidemiol; 2013; 67(1):75-9, 157-60. PubMed ID: 23745380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. There is much to be learnt about the costs of multiple sclerosis in Latin America.
    Romano M; Machnicki G; Rojas JI; Frider N; Correale J
    Arq Neuropsiquiatr; 2013 Aug; 71(8):549-55. PubMed ID: 23982015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
    Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
    J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and indirect economic consequences of multiple sclerosis in Ireland.
    Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
    Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on healthcare resource utilization of multiple sclerosis in Spain.
    Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
    BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
    Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
    J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic costs associated with an MS relapse.
    O'Connell K; Kelly SB; Fogarty E; Duggan M; Buckley L; Hutchinson M; McGuigan C; Tubridy N
    Mult Scler Relat Disord; 2014 Nov; 3(6):678-83. PubMed ID: 25891546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group.
    Can J Neurol Sci; 1998 Feb; 25(1):23-30. PubMed ID: 9532277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of multiple sclerosis in the UK, Germany and France.
    Murphy N; Confavreux C; Haas J; König N; Roullet E; Sailer M; Swash M; Young C; Mérot JL;
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):607-22. PubMed ID: 17165327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.
    Bruno D; Marc D; Ouarda P; Dominique S; Marc S; Laurène C; Khalil J; Jonathan E; Francis G
    Mult Scler Relat Disord; 2019 Nov; 36():101396. PubMed ID: 31525627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of the financial costs of multiple sclerosis at different stages of the disease.
    Orlewska E; Mierzejewski P; Zaborski J; Kruszewska J; Wicha W; Fryze W; Drozdowski W; Skibicka I; Mirowska-Guzel D; Czlonkowski A; Czlonkowska A
    Eur J Neurol; 2005 Jan; 12(1):31-9. PubMed ID: 15613144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.
    Casado V; Martínez-Yélamos S; Martínez-Yélamos A; Carmona O; Alonso L; Romero L; Moral E; Gubieras L; Arbizu T
    BMC Health Serv Res; 2006 Nov; 6():143. PubMed ID: 17078879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
    da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
    BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
    Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
    Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The indirect costs of multiple sclerosis: systematic review and meta-analysis.
    Stawowczyk E; Malinowski KP; Kawalec P; Moćko P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):759-86. PubMed ID: 26189826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.